Impact of Brokerage Rating on Akorn, Inc.(AKRX)

Many Akorn, Inc.(AKRX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Akorn was Initiated by Goldman to Sell on Dec 1, 2016.

Company has reported several Insider transactions to the SEC, on Aug 16, 2016, Kenneth Abramowitz (director) sold 2,691 shares at 30.46 per share price.On Jun 14, 2016, Joseph Bonaccorsi (Sr VP Gen Counsel & Secretary) sold 6,500 shares at 29.84 per share price.On Jun 9, 2016, Ronald M Johnson (director) sold 7,542 shares at 31.49 per share price.

Akorn Last issued its quarterly earnings results on Nov 3, 2016. The company reported $0.56 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $0.54. The company had revenue of $284.10 million for the quarter, compared to analysts expectations of $266.70 million. The companys revenue was up 10.6% compared to the same quarter last year.

Akorn, Inc. (NASDAQ:AKRX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.08 by 12 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 5 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.

Akorn, Inc. (NASDAQ:AKRX): The stock price is expected to reach $ 27.9 in the short term. The number of analysts agreeing with this consensus is 10. The higher estimate for the short term price target is at $36 while the lower estimate is at $22. The standard deviation of the price stands at $5.99.

Akorn, Inc. (NASDAQ:AKRX) rose 4.39% or 0.91 points on Tuesday and made its way into the gainers of the day. After trading began at $20.74 the stock was seen hitting $21.7 as a peak level and $20.65 as the lowest level. The stock ended up at $21.65. The daily volume was measured at 1,217,731 shares. The 52-week high of the share price is $35.4 and the 52-week low is $17.57. The company has a market cap of $2,711 million.

Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services.

Akorn,

For any feedback and suggestions contact author at Andy.Clarke@thefoundersdaily.com

Add Comment